Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Progyny Inc Market Cap
Based on ratings from 11 stock analysts, the Progyny Inc stock price is expected to increase by 23.64% in 12 months. This is calculated by using the average 12-month stock price forecast for Progyny Inc. The lowest target is $17 and the highest is $22. Please note analyst price targets are not guaranteed and could be missed completely.
About 11 Wall Street analysts have assignedPGNY 5 buy ratings, 6 hold ratings, and 0 sell ratings. This means that analysts expect Progyny Inc to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on PGNY. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of PGNY.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Sarah James Barclays | Overweight | $17 | Maintains | Nov 14, 2024 |
| Michael Cherny B of A Securities | Buy | $21 | Maintains | Nov 13, 2024 |
| Richard Close Canaccord Genuity | Hold | $17 | Maintains | Nov 13, 2024 |
| Jailendra Singh Truist Securities | Hold | $19 | Downgrade | Nov 13, 2024 |
| Sarah James Cantor Fitzgerald | Overweight | $25 | Reiterates | Oct 1, 2024 |
| Richard Close Canaccord Genuity | Hold | $18 | Maintains | Sep 20, 2024 |
| Anne Samuel JP Morgan | Overweight | $22 | Maintains | Sep 19, 2024 |
| Constantine Davides JMP Securities | Market Perform | Downgrade | Sep 19, 2024 | |
| Sarah James Cantor Fitzgerald | Overweight | $25 | Maintains | Sep 19, 2024 |
| Michael Cherny Leerink Partners | Market Perform | $21 | Maintains | Sep 19, 2024 |
| Glen Santangelo Jefferies | Buy | $24 | Maintains | Sep 19, 2024 |
| Jailendra Singh Truist Securities | Buy | $26 | Maintains | Sep 19, 2024 |
| Sarah James Cantor Fitzgerald | Overweight | $37 | Reiterates | Aug 20, 2024 |
| Anne Samuel JP Morgan | Overweight | $31 | Maintains | Aug 19, 2024 |
| Constantine Davides JMP Securities | Market Outperform | $31 | Maintains | Aug 7, 2024 |
| David Larsen BTIG | Neutral | Downgrade | Aug 7, 2024 | |
| Sarah James Cantor Fitzgerald | Overweight | $37 | Maintains | Aug 7, 2024 |
| Michael Cherny Leerink Partners | Market Perform | $25 | Downgrade | Aug 7, 2024 |
| Richard Close Canaccord Genuity | Hold | $24 | Downgrade | Aug 7, 2024 |
| Jailendra Singh Truist Securities | Buy | $33 | Maintains | Aug 7, 2024 |
When did it IPO
2019
Staff Count
563
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Mr. Peter Anevski CPA
Market Cap
$1.32B
In 2023, PGNY generated $1.09B in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that PGNY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 26 Nov 2024
Sentiment - NEGATIVE
Source - Seeking Alpha
Summary - Progyny's rating has been downgraded from buy to hold after Q3 2024 results missed expectations, prompting lowered FY24 guidance and concerns over declining demand for ART cycles.
Why It Matters - Progyny's downgrade reflects declining growth confidence, disappointing Q3 results, and lowered guidance, signaling potential risks to revenue and demand that could impact stock performance.
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Johnson Fistel, LLP is investigating Progyny, Inc. (NASDAQ: PGNY) for potential securities law violations related to misrepresentation and disclosure failures affecting investors.
Why It Matters - The investigation into Progyny for potential securities law violations may indicate financial instability, leading to increased risks for investors regarding stock value and recovery of losses.
Sun, 17 Nov 2024
Sentiment - NEGATIVE
Source - Seeking Alpha
Summary - Progyny's stock has dropped 60% in 2024, losing Amazon as a client. Q3 financials show minimal growth, declining margins, and lower EPS. The analyst has sold shares, citing increased competition.
Why It Matters - Progyny's 60% stock drop and loss of a major client signal deteriorating performance. Weak financials and management challenges raise concerns about future profitability and competitive position.
Thu, 14 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Progyny, Inc. (Nasdaq: PGNY) executives will speak at the Jefferies London Healthcare Conference on November 19, 2024, at 8:00 a.m. GMT.
Why It Matters - Progyny's CEO and CFO participating in a prominent healthcare conference could signal strategic insights or updates, influencing investor sentiment and stock performance.
Wed, 13 Nov 2024
Sentiment - NEGATIVE
Source - Benzinga
Summary - Progyny, Inc. (PGNY) reported third-quarter sales results that missed expectations and provided FY24 revenue guidance that is below analyst estimates.
Why It Matters - Progyny's lower-than-expected sales and FY24 guidance may signal weakening demand, impacting future profitability and stock performance, leading to potential investor caution.
Wed, 13 Nov 2024
Sentiment - NEGATIVE
Source - The Motley Fool
Summary - Progyny's stock experienced a significant decline today, though specific reasons for the crash were not detailed in the provided excerpt. Investors should monitor further developments.
Why It Matters - A stock crash signals potential financial instability or loss of investor confidence, affecting market perception and future growth prospects, leading to reevaluation of investment strategies.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
